Integrated Solutions for Complex Drug Development

Sponsored by Pace® Life Sciences

As drug modalities grow increasingly complex—spanning biologics, cell and gene therapies, antibody drug conjugates, and combination formats—CDMOs are pivoting their tactics to support these modalities. Frank Tagliaferri, PhD, Chief Scientific Officer at Pace® Life Sciences, explains how Pace Analytical expanded into a broad-based CDMO serving clients across the drug development lifecycle, from late discovery through commercial products. Growth came through a combination of targeted acquisitions and organic investment, adding capabilities such as clinical trial manufacturing, regulatory consulting, and advanced analytical testing across multiple locations. This led to the creation of a platform model that focuses on anticipating client needs and accelerating access to data to support faster decision-making throughout the drug development process.